208 related articles for article (PubMed ID: 9258954)
1. Endometrial carcinomas--flow cytometric DNA content and S-phase values.
Jacobsen M; Jakobsen A; Nedergaard L; Andersen JE; Nielsen K
Pathol Res Pract; 1997; 193(4):283-90. PubMed ID: 9258954
[TBL] [Abstract][Full Text] [Related]
2. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
[TBL] [Abstract][Full Text] [Related]
3. [Cytophotometric studies for evaluating the prognosis in endometrial cancer].
Köhler U; Krug H; Taubert G
Zentralbl Gynakol; 1991; 113(24):1371-9. PubMed ID: 1808964
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of flow cytometric and clinical variables in endometrial adenocarcinoma stages I and II.
Wagenius G; Bergström R; Strang P; Gerdes U; Rogo K; Tribukait B; Stendahl U
Anticancer Res; 1992; 12(3):725-32. PubMed ID: 1622130
[TBL] [Abstract][Full Text] [Related]
5. The significance of the amount of myometrial invasion in patients with Stage IB endometrial carcinoma.
Alektiar KM; McKee A; Lin O; Venkatraman E; Zelefsky MJ; Mychalczak BR; McKee B; Hoskins WJ; Barakat RR
Cancer; 2002 Jul; 95(2):316-21. PubMed ID: 12124832
[TBL] [Abstract][Full Text] [Related]
6. Adenomyosis is associated with myometrial invasion by FIGO 1 endometrial adenocarcinoma.
Ismiil ND; Rasty G; Ghorab Z; Nofech-Mozes S; Bernardini M; Thomas G; Ackerman I; Covens A; Khalifa MA
Int J Gynecol Pathol; 2007 Jul; 26(3):278-83. PubMed ID: 17581412
[TBL] [Abstract][Full Text] [Related]
7. [A study on DNA content and cell cycle phase analysis in endometrial carcinoma].
Xue F; Jiao S; Zhao F
Zhonghua Fu Chan Ke Za Zhi; 1996 Apr; 31(4):216-9. PubMed ID: 8758776
[TBL] [Abstract][Full Text] [Related]
8. Adenomyosis involved by endometrial adenocarcinoma is a significant risk factor for deep myometrial invasion.
Ismiil N; Rasty G; Ghorab Z; Nofech-Mozes S; Bernardini M; Ackerman I; Thomas G; Covens A; Khalifa MA
Ann Diagn Pathol; 2007 Aug; 11(4):252-7. PubMed ID: 17630108
[TBL] [Abstract][Full Text] [Related]
9. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
[TBL] [Abstract][Full Text] [Related]
10. DNA content as a prognostic factor in endometrial carcinoma.
Newbury R; Schuerch C; Goodspeed N; Fanning J; Glidewell O; Evans M
Obstet Gynecol; 1990 Aug; 76(2):251-7. PubMed ID: 2371030
[TBL] [Abstract][Full Text] [Related]
11. DNA ploidy is an independent prognostic indicator of overall survival in stage I endometrial endometrioid carcinoma.
Santala M; Talvensaari-Mattila A
Anticancer Res; 2003; 23(6D):5191-6. PubMed ID: 14981988
[TBL] [Abstract][Full Text] [Related]
12. Role of DNA ploidy analysis in endometrial adenocarcinoma.
Jhala DN; Atkinson BF; Balsara GR; Hernandez E; Jhala NC
Ann Diagn Pathol; 2001 Oct; 5(5):267-73. PubMed ID: 11598854
[TBL] [Abstract][Full Text] [Related]
13. Prospective multicenter validation confirms the prognostic superiority of the endometrial carcinoma prognostic index in international Federation of gynecology and obstetrics stage 1 and 2 endometrial carcinoma.
Baak JP; Snijders W; van Diermen B; van Diest PJ; Diepenhorst FW; Benraadt J
J Clin Oncol; 2003 Nov; 21(22):4214-21. PubMed ID: 14615450
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma.
Pfisterer J; Kommoss F; Sauerbrei W; Rendl I; Kiechle M; Kleine W; Pfleiderer A
Gynecol Oncol; 1995 Aug; 58(2):149-56. PubMed ID: 7622098
[TBL] [Abstract][Full Text] [Related]
15. Residual myometrial invasion after intracavitary irradiation of endometrial adenocarcinoma stages I and II. Relations to DNA content and S-phase rate.
Wagenius G; Strang P; Boman K; Tribukait B; Stendahl U
In Vivo; 1988; 2(3-4):243-5. PubMed ID: 2979839
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic evaluation of endometrial carcinoma by DNA content and histologic factors].
Shimizu K
Nihon Sanka Fujinka Gakkai Zasshi; 1995 Apr; 47(4):413-8. PubMed ID: 7730696
[TBL] [Abstract][Full Text] [Related]
17. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of cell kinetics in endometrial adenocarcinoma.
Mariani L; Conti L; Antenucci A; Vercillo M; Atlante M; Gandolfo GM
Anticancer Res; 2000; 20(5B):3569-74. PubMed ID: 11131664
[TBL] [Abstract][Full Text] [Related]
19. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
Orezzoli JP; Sioletic S; Olawaiye A; Oliva E; del Carmen MG
Gynecol Oncol; 2009 Jun; 113(3):316-23. PubMed ID: 19345400
[TBL] [Abstract][Full Text] [Related]
20. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 1999 Sep; 74(3):385-94. PubMed ID: 10479498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
